![logo](/logos/TSHA.webp)
Taysha Gene Therapies, Inc.
NASDAQ:TSHA
2.04 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Taysha Gene Therapies, Inc. |
Symbool | TSHA |
Munteenheid | USD |
Prijs | 2.04 |
Beurswaarde | 418,083,720 |
Dividendpercentage | 0% |
52-weken bereik | 1.27 - 4.32 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Sean P. Nolan |
Website | https://www.tayshagtx.com |
An error occurred while fetching data.
Over Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)